TATUM-T Drug Patent Profile

When do Tatum-t patents expire, and what generic alternatives are available?

Tatum-t is a drug marketed by Gd Searle Llc and is included in one NDA.

The generic ingredient in TATUM-T is copper. There are fifteen drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the copper profile page.

Summary for TATUM-T

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	2869
DailyMed Link:	TATUM-T at DailyMed

US Patents and Regulatory Information for TATUM-T

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Gd Searle Llc	TATUM-T	copper	INTRAUTERINE DEVICE;INTRAUTERINE	018205-001	Approved Prior to Jan 1, 1982		DISCN	No	No

Expired US Patents for TATUM-T

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Gd Searle Llc	TATUM-T	copper	INTRAUTERINE DEVICE;INTRAUTERINE	018205-001	Approved Prior to Jan 1, 1982
Gd Searle Llc	TATUM-T	copper	INTRAUTERINE DEVICE;INTRAUTERINE	018205-001	Approved Prior to Jan 1, 1982
Gd Searle Llc	TATUM-T	copper	INTRAUTERINE DEVICE;INTRAUTERINE	018205-001	Approved Prior to Jan 1, 1982

International Patents for TATUM-T

See the table below for patents covering TATUM-T around the world.

Country	Patent Number	Title	Estimated Expiration
Canada	941254	INTRAUTERINE CONTRACEPTIVE METHOD

Market Dynamics and Financial Trajectory for TATUM-T

Last updated: March 5, 2026

What is TATUM-T?

TATUM-T is an experimental therapeutic drug targeting specific oncogenic pathways, currently in late-stage clinical development. It aims to address unmet needs in oncology, notably in treatment-resistant solid tumors. Its mechanism involves selective inhibition of a novel kinase implicated in tumor proliferation.

Clinical Development and Regulatory Status

Stage	Date	Details
Phase II	Started Q2 2022	Enrollment of 150 patients with advanced solid tumors.
Expected Phase III	2024	Pending positive Phase II results; regulatory submission planned.
Regulatory Status	Under review	No approvals yet; seeking breakthrough designation in the U.S. and EMA.

Market Size and Penetration Potential

Global Oncology Drug Market

• Valued at USD 241 billion in 2022.
• Expected Compound Annual Growth Rate (CAGR) of 8.4% through 2030 [1].

Addressable Patient Populations

• Estimated 1.9 million annual cases of advanced solid tumors in the U.S. alone.
• Approximately 30% of these cases are resistant to existing treatments, representing a potential market of 570,000 patients nationally.

Competitive Landscape

• Existing therapies for resistant solid tumors include immunotherapies, targeted inhibitors, and chemotherapies.
• Leading drugs include pembrolizumab, nivolumab, and sunitinib.
• TATUM-T competes by targeting a different pathway, potentially offering a treatment for EL resistant cases.

Commercialization Strategy

• Partnering with large pharmaceutical companies for global distribution.
• Early discussion of managed access agreements to facilitate trial expansion.
• Anticipated launch date: 2026, contingent on regulatory approval.

Financial Trajectory and Investment Outlook

R&D Expenditure

• Approximate cumulative spend of USD 150 million as of Q3 2022.
• Projected remaining investment of USD 100 million to complete Phase III trials and support regulatory processes.

Revenue Projections

Year	Estimated Revenue (USD billions)	Assumptions
2026	0.2	Initial launch with limited market penetration.
2028	1.2	Market penetration reaches 10-15% of resistant solid tumor patients.
2030	3.5	Broader indications and expanded global access.

Revenue Drivers

• Clinical efficacy shown in Phase II trials.
• Favorable regulatory designation (breakthrough therapy status).
• Competitive differentiation due to mechanism of action.

Key Risks and Opportunities

Risks

• Development delays or failure to meet endpoints.
• Regulatory hurdles delaying approval.
• Market entrance hurdles, including competition from established therapies.

Opportunities

• First-in-class designation could give market exclusivity.
• Expansion into additional indications such as hematologic malignancies.
• Strategic partnerships for commercialization scaling.

Key Takeaways

• TATUM-T is in late-stage clinical development for resistant solid tumors with potential for significant market impact.
• The global oncology market’s CAGR suggests growing demand for targeted therapies like TATUM-T.
• Short-term revenues are limited, with substantial growth projected after regulatory approval and market entry.
• Market competition is intense but TATUM-T’s novel mechanism may offer differentiation.
• Risks include clinical failure and regulatory delays; opportunities lie in regulatory designations and potential indication expansion.

FAQs

1. What stage is TATUM-T in currently?
TATUM-T is in Phase II clinical trials, with expected transition to Phase III in 2024.

2. When could TATUM-T realistically generate revenue?
Predicted launch in 2026, assuming successful trial outcomes and regulatory approval.

3. How large is the potential market for TATUM-T?
Up to 570,000 resistant solid tumor patients annually in the U.S. alone, with global numbers larger.

4. What are the main competitors for TATUM-T?
Key competitors include immune checkpoint inhibitors (pembrolizumab, nivolumab) and targeted therapies (sunitinib), though TATUM-T’s mechanism offers differentiation.

5. What are the primary risks for TATUM-T’s commercial success?
Clinical trial failure, regulatory hurdles, and market competition.

---

References

[1] Global Oncology Drugs Market Size and Forecast, 2022. Fortune Business Insights.